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Abstract: Although rare, hepatoblastoma is the most common pediatric liver tumor. Complete 
resection is a critical component for cure; however, most patients will have tumors that are not 
resected at diagnosis. For these patients, administration of neoadjuvant chemotherapy renders 
tumors resectable in most patients. For patients whose tumors remain unresectable after che-
motherapy, liver transplantation is indicated (in the absence of active unresectable metastatic 
disease). In patients whose tumors remain unresectable after conventional chemotherapy, inter-
ventional techniques may serve as a promising option to reduce tumor size, decrease systemic 
toxicity, decrease need for liver transplantation, and increase feasibility of tumor resection.
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Introduction
Although rare, hepatoblastoma (HB) is the most common pediatric liver tumor with 
at least 100 cases per year in the US and an increasing incidence.1–4 Patients with HB 
typically present at <5 years of age, with an increased risk seen in patients with low 
birthweight, maternal tobacco exposure, familial adenomatous polyposis coli, and 
Beckwith–Wiedemann Syndrome.5–8
Complete resection is a critical component for cure; however, 60%–80% of 
patients’ tumors are unresectable at diagnosis depending upon the surgical guidelines 
used.9,10 The surgery-based Evans staging system, previously used in America, was 
based on an attempted resection at diagnosis in all patients. It classified tumors as 
stage I (upfront resection with negative microscopic margins), stage II (upfront resec-
tion with positive microscopic margins), stage III (unresectable at diagnosis without 
metastatic disease), and stage IV (metastatic disease). In the intergroup study INT0098 
(1989–1992), 32% of patients were presented with stage I or II disease and 68% of 
patients were presented with stage III or IV tumors.9 In Europe, the International Child-
hood Liver Tumors Strategy Group (SIOPEL) introduced a radiology-based staging 
system called PRETreatment EXTent of disease (PRETEXT).11 The PRETEXT system 
classifies tumors into one of four groups based upon the number of tumor free liver 
sections. PRETEXT I tumors have three adjoining sectors free of tumor, PRETEXT 
II tumors have two adjoining sectors free of tumor, PRETEXT III tumors have one 
sector free of tumor, and PRETEXT IV tumors have no sectors free of tumor. In the 
most recent high risk (HR) SIOPEL trial SIOPEL 4 (which included patients with 
metastatic disease, PRETEXT IV tumors, extrahepatic abdominal  disease, vascular 
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invasion, and/or low alpha fetoprotein), the patients had 3%, 
27%, 44%, and 26% PRETEXT I, II, III, and IV tumors, 
respectively.12 In the most recent standard risk (SR) SIOPEL 
trial SIOPEL 3SR (which included patients without HR fea-
tures), the patients had 8%, 52%, and 40% PRETEXT I, II, 
and III tumors, respectively.13 In the most current Children’s 
Oncology Group trial AHEP0731, the surgical guidelines 
were structured according to PRETEXT. Resection at diag-
nosis was recommended only for patients with PRETEXT 
I and II tumors with a 1 cm radiographic margin from the 
middle hepatic vein, the retrohepatic inferior vena cava, and 
the portal bifurcation. Following neoadjuvant chemotherapy, 
conventional resection is recommended for patients with 
resolution of major vascular involvement and POSTTEXT 
I, II, or III group. POSTTEXT refers to the tumor burden 
after neoadjuvant chemotherapy.
When tumors remain unresectable after chemotherapy, 
various therapeutic approaches may be employed to facilitate 
resection. These include consideration of liver transplanta-
tion, aggressive nonanatomic resection with vascular recon-
struction, and/or interventional embolization depending on 
the tumor extent and available expertise.
Chemotherapy
Neoadjuvant chemotherapy allows for delayed resection of 
the primary mass in some patients with HB; however, certain 
tumors remain amenable to complete resection only via liver 
transplantation. Cisplatin is generally considered to be the 
most active chemotherapy agent in HB treatment and has 
significantly affected rates of surgical resection and overall 
survival and is administered alone or in combination with 
other chemotherapeutic agents (with doxorubicin being the 
second most common agent utilized).14,15 Of note, previous 
studies have not performed a direct comparison of cisplatin 
with doxorubicin to determine which is the more active agent 
in HB treatment. For more advanced HB (including tumors 
with vascular involvement and those that are PRETEXT IV 
or metastatic at diagnosis), treatment has been based on mul-
tiagent chemotherapy with a cisplatin backbone. For patients 
with less advanced tumors (eg, tumors without significant 
vascular involvement), the aim has been to maintain overall 
survival while decreasing chemotherapy toxicity.
Comparison of different chemotherapeutic regimens 
has been difficult due to different staging systems, risk 
stratification schema, and surgical approaches utilized by 
cooperative groups. Resectability in less advanced tumors 
is often determined by the expertise, approach, and prefer-
ence of the treating surgeon. In addition, in North America, 
the emphasis has been to resect at diagnosis when possible, 
whereas delayed resection has been advocated in European 
studies. Event-free survival in patients with HB not resected 
at diagnosis varies depending on additional prognostic fac-
tors as well as the different staging systems and surgical 
approaches but generally approaches at least ~65%–70% 
(Table 1). The upcoming international trial will be based on 
resection at diagnosis when possible and will utilize a single-
risk stratification system. Nonetheless, general retrospective 
comparisons can be made between the different treatment 
regimens (Table 1).
Chemotherapy for unresectable HB in North America 
has historically been based on a cisplatin backbone in com-
bination with 5-fluorouracil and vincristine (C5V) and, most 
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recently, addition of doxorubicin (C5VD) for upfront unre-
sectable patients. In INT0098, 47 patients with unresectable 
HB (45% of those with tumors not resected at diagnosis and 
eligible for a delayed resection) underwent complete resection 
after neoadjuvant chemotherapy.9 These patients received in 
a randomized manner either C5V or cisplatin/doxorubicin 
before the definitive surgery. On close inspection of the 
INT0098 results, the cisplatin/doxorubicin regimen was actu-
ally superior to C5V in terms of disease progression; however, 
due to excess toxicity, the eventual survival was not statisti-
cally different. Given that supportive care measures have 
improved since then, and with some favorable results from 
European regimens including doxorubicin, it was decided for 
the current trial (AHEP0731) that patients with stage III HB 
should have doxorubicin added to C5V (C5VD). Analysis of 
patients proceeding to conventional resection or liver trans-
plantation after this new regimen is pending.
Chemotherapy for HB not resected at diagnosis in Europe 
has consisted of cisplatin alone for patients with SR HB 
(localized, PRETEXT I, II, or III tumors) or a combination 
with carboplatin and doxorubicin for patients with HR HB 
(PRETEXT IV, metastatic disease, or other HR features on 
SIOPEL IV).12,13,16 In SIOPEL 3SR, 126 patients received 
either cisplatin monotherapy or cisplatin and doxorubicin 
with 95% and 93% of patients, respectively, able to undergo 
delayed complete resection.13 In SIOPEL 3HR, 150 patients 
received either cisplatin, carboplatin, and doxorubicin with 
56% able to undergo delayed conventional resection and 
21% proceeding to liver transplantation.16 The subsequent 
SIOPEL study for HR HB (SIOPEL IV) incorporated inten-
sification of the timing of the cisplatin dosing in combination 
with carboplatin and doxorubicin.12 In SIOPEL IV, 74% of 
patients were able to undergo delayed complete resection 
(35% with liver transplantation and the remaining 65% with 
conventional resection).
Taking into account all patients with unresectable HB, 
there is a subset of patients, as seen in SIOPEL 3SR, for whom 
less chemotherapy is indicated.13 Acute and late toxicities 
from chemotherapy are significant for patients with HB. The 
common acute side effects include myelosuppression, malnu-
trition, febrile neutropenia, and neuropathy. The late effects of 
chemotherapy for HB include hearing loss, cardiomyopathy, 
nephrotoxicity, and second neoplasms. Further reduction in 
chemotherapy exposure with fewer agents and lower cumula-
tive doses will be studied on the upcoming international trial 
for patients with less advanced HB not resected at diagnosis.
For the higher risk population with unresectable HB 
without metastatic disease, the optimal chemotherapeutic 
approach remains to be determined. For patients with unre-
sectable HB not amenable to conventional resection, liver 
transplantation is the mainstay for cure. Prolonged chemo-
therapy administration beyond four cycles in an attempt to 
proceed with conventional resection has been shown to be 
ineffective in increasing the ability to proceed to conventional 
resection and may induce drug resistance.17,18
Surgical approaches
The recommendations for transplant used in the most recent 
cooperative group studies are: 1) tumor at diagnosis clearly 
involving all four sections of the liver, especially those with 
extensive multifocality as judged by MRI or CT angiography 
and 2) tumor location so close to both main portal vessels 
at the hilum of the liver and/or all three hepatic veins that it 
is unlikely that a tumor-free excision plane will be achieved 
without risking life-threatening hemorrhage. These patients 
should be identified early in their treatment, and their clinical 
course and imaging should be followed closely throughout 
their initial chemotherapy in consultation with a surgeon 
from a liver specialty center. An occasional patient with an 
extensively multifocal PRETEXT IV tumor or with tumor 
thrombosis in the main portal vein might be recommended 
for primary transplant with minimal preoperative chemo-
therapy.19 The upcoming international trial for HB (Pediatric 
Hepatic International Tumor Trial) will incorporate risk strati-
fication by the Children’s Hepatic Tumors International Col-
laboration including surgical guidelines based on PRETEXT.
Multifocal PRETEXT IV HB in the absence of any 
metastatic disease after chemotherapy (POSTTEXT IV + 
multifocal/F – metastases/M) is a clear indication for liver 
transplantation. Clinicians should resist the temptation to 
intensify chemotherapy in a vain effort to avoid transplant 
because of the high likelihood of inducing tumor resistance to 
chemotherapy.17,18 Apparent clearance of tumor nodules from 
one section of liver after preoperative chemotherapy should 
not distract from transplant because of the high probability 
of persistent microscopic viable neoplastic cells despite 
 apparent radiographic clearance.10 Children’s Oncology 
Group and SIOPEL recommend transplant in these patients, 
although there are reports of successful piecemeal resections 
of such tumors.20 The patients with large solitary PRETEXT 
IV tumors usually receive neoadjuvant chemotherapy, and 
many of these tumors may “downstage” to POSTTEXT 
III with clear retraction of the tumor from the anatomic 
border of one lateral section, allowing for performance of a 
trisectionectomy. A unifocal POSTTEXT IV tumor without 
metastatic disease is a clear indication for transplant.





In a subgroup of patients with PRETEXT II and III 
tumors, there will be major vascular invasion that does not 
clear with neoadjuvant chemotherapy. For patients with 
persistent vascular involvement of all three major hepatic 
veins, both portal veins, and/or the retrohepatic vena cava 
(POSTTEXT + venous involvement/V and/or + portal 
involvement/P), referral for nonconventional liver resection 
or liver transplantation is recommended. Resection in the 
face of major venous invasion runs the risk of leaving viable 
neoplastic tissue behind if the surgeon peels off viable tumor 
directly from the involved vein. Some have argued in favor 
of venous resection and reconstruction (“extreme” or “com-
plex” resection) as opposed to transplant in these cases.21
Unresponsive or progressive metastatic disease in the face 
of neoadjuvant chemotherapy is a relative contraindication 
to transplant because even if the nodules can be surgically 
resected, microscopic foci of chemoresistant tumor are 
highly probable.22–24 Lung metastases in a patient that seem 
to respond to chemotherapy, but which do not entirely clear, 
should be surgically resected.10,25 Some have advocated ster-
notomy and bilateral lung palpation, rather than unilateral 
wedge resection, although this remains controversial.
Interventional approaches
Interventional radiology is defined as the use of imaging 
techniques to guide a minimally invasive procedural inter-
vention. Interventional techniques have long been utilized in 
pediatrics to obtain central venous access, image the vascular 
tree, obtain diagnostic tissue via needle biopsy, drain fluid 
collections, and perform genitourinary and gastroenterology 
procedures.26,27 While the use of interventional techniques to 
treat adult oncology patients is well established, the translation 
of these techniques to the pediatric realm continues to evolve. 
This evolution has been limited by the slow development and 
approval of new devices for use in children, patient size limi-
tations, and the hesitation to test novel treatment approaches 
in pediatric patients.28 There are numerous interventional 
radiology modalities available for the treatment of oncology 
patients, particularly those with liver tumors, with a range of 
experiences already published in the adult literature.29–32 More 
recently, these interventional approaches have been intro-
duced to the pediatric population as detailed in the following.
Transarterial chemoembolization (TACE) has been widely 
used in adult hepatocellular carcinoma (HCC) and secondary 
(colon cancer) liver metastases. It provides the advantage of 
concentrated chemotherapy administration, increased dwell 
time, and decreased systemic toxicity.29 For hepatic metas-
tases and HCC, TACE can not only be used in combination 
with radiofrequency ablation (RFA) to treat diffuse disease 
but may also serve as a neoadjuvant approach to improve the 
feasibility of local control options such as surgical resection 
or orthotopic liver transplant.30,31,33 TACE and RFA have been 
trialed in pediatric oncology patients, with patient selection and 
suitability for intervention extrapolated from the adult experi-
ence. Presurgical TACE has been used for pediatric HB in an 
attempt to reduce tumor volume and aid with surgical inter-
vention. Published series are of various sizes and document a 
combination of chemotherapeutic agents used. However, nearly 
all cases demonstrate reduction in tumor size and resultant 
intratumoral necrosis and decreased intraoperative bleeding. 
While many publications reported increased ease of surgical 
resection, not all cases resulted in a complete resection.34–36
High-intensity frequency ultrasound is a technique that 
allows for the focal delivery of high-intensity ultrasound 
beams directly to the tumor to enhance cell death. High-
intensity frequency ultrasound has been trialed with variable 
success, in combination with TACE, in the pediatric HB 
patients with upfront unresectable or metastatic tumors.37,38 
Transarterial radioembolization with yttrium-90, while 
routinely pursued in the adult community, is relatively new 
to the pediatric community with experiential case reports 
limited to the palliative setting.39
While RFA has been used extensively in adult liver tumor 
patients, it has been trialed sparingly in pediatric patients. 
RFA has the benefit of providing immediate pain relief with 
a more targeted focus than conventional radiotherapy.40 Its 
use has been reported successfully, albeit for small num-
bers, in patients with recurrent HB and Wilms tumor liver 
metastases and in a Phase I/pilot study for all solid tumors 
in which one patient with fibrolamellar HCC underwent 
multiple procedures.40–43 Postprocedural pain was moderate 
with prolonged hospitalization more frequently reported. 
Serious complications were more commonly seen secondary 
to pulmonary RFA for lung lesions.
Radiation therapy
Few cases have been reported in the literature incorporating 
external beam radiation therapy for patients with unresect-
able HB. Radiation therapy is not indicated during the 
initial treatment of HB, and its role in recurrent HB or in 
HB not resectable by other means (including patients who 
are not candidates for liver transplantation) remains to be 
determined.44–46
Stem cell transplantation
Autologous stem cell transplantation has been explored for 
patients during upfront treatment as well as in relapse; thus 
far, it has not been proven beneficial.47,48 The specific role of 





stem cell transplantation in rendering HB tumors resectable 
remains undetermined but is likely to add toxicity in patients 
who may otherwise be candidates for liver transplantation 
instead of conventional resection.49
Conclusion
For patients with HB, resection of the primary tumor (and 
metastatic sites where applicable) is the goal for curative 
treatment. When tumors are deemed to be unresectable at 
diagnosis, chemotherapy can be utilized to render most of 
them resectable. For patients without active metastatic disease 
but with primary tumors not amenable to conventional resec-
tion, liver transplantation is indicated. It stands to reason that 
for patients with upfront unresectable disease, interventional 
techniques may serve as a promising option to reduce tumor 
size, decrease systemic toxicity, and increase ease of tumor 
resectability. The upcoming international trial for HB aims 
to decrease toxicity from chemotherapy for patients with 
unresectable HB while maintaining good survival.
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